India  
 
NewsR.in

Dow Jumps 210 Points On Vaccine News From AstraZeneca

Video Credit: Wochit News - Duration: 00:37s - Published
Dow Jumps 210 Points On Vaccine News From AstraZeneca

Dow Jumps 210 Points On Vaccine News From AstraZeneca

On Monday, US stocks rose.

AstraZeneca said its COVID-19 vaccine candidate demonstrated an average efficacy rate of 70%.

This is the third COVID-19 vaccine said to have surpassed the Food and Drug Administration's requirement of 50% effectiveness.

S&P 500: 3,580.82, up 0.7% Dow Jones industrial average: 29,473.41, up 0.7% (210 points) Nasdaq composite: 11,929.04, up 0.6%


You Might Like


Related videos from verified sources

Moderna to Submit COVID-19 Vaccine for FDA Regulatory Approval [Video]

Moderna to Submit COVID-19 Vaccine for FDA Regulatory Approval

Moderna to Submit COVID-19 Vaccine for FDA Regulatory Approval. Moderna will submit its coronavirus vaccine on Nov. 30. It is the second drugmaker to ask the FDA for emergency use..

Credit: Wibbitz Top Stories     Duration: 01:03Published
Covid-19 vaccine to be distributed initially in India says Serum Institute CEO [Video]

Covid-19 vaccine to be distributed initially in India says Serum Institute CEO

The CEO of India's Serum Institute says India will get supplies of the Oxford-AstraZeneca vaccine that his organisation produces, first.

Credit: Newsflare STUDIO     Duration: 01:28Published
Oxford Astra Zeneca's vaccine error | What happens to India trials? | Oneindia News [Video]

Oxford Astra Zeneca's vaccine error | What happens to India trials? | Oneindia News

Even as Oxford and Astra Zeneca said that their Covid-19 vaccine had a 90% efficacy, their claims it turned out were based on an accident. Oxford Astrazeneca said that when volunteers were administered..

Credit: Oneindia     Duration: 01:25Published